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2344HISTORICAL CONTEXT
There have been 3 prior documents, all sponsored by
the American College of Cardiology (ACC) (1–3), that
addressed eligibility and disqualiﬁcation criteria for com-
petitive athletes with cardiovascular diseases: Bethesda
Conferences 16 (1985), 26 (1994), and 36 (2005), published
and used over a 30-year period. Each of the 3 initiatives
(and the present American Heart Association (AHA)/ACC
scientiﬁc statement) were driven by the tenet that young
trained athletes with underlying cardiovascular abnor-
malities are likely at some increase in risk for sudden
cardiac death (usually on the athletic ﬁeld) compared to
nonathletes or competitive athletes without cardiovas-
cular disease (4–8).
All 3 Bethesda Conferences and the present derived
AHA/ACC document provide expert consensus recom-
mendations. These insights use 1) the experience and
expertise of the panelists (i.e., individual and collective
judgments, using the “art of medicine”) and 2) available
scientiﬁc evidence that estimates the medical risk in
athletes with underlying acquired, genetic, and congen-
ital heart abnormalities imposed by the unique lifestyle of
engagement in competitive sports.
These insights can be applied to decision making for
temporary or permanent disqualiﬁcation versus eligibility
of athletes with probable or conclusive evidence of car-
diovascular disease; however, the scientiﬁc data sup-
porting many of the recommendations in this document
are unavoidably limited, as evidenced by the frequent
assignment of a Level of Evidence C. Nevertheless, each
of the 3 prior Bethesda Conferences has served the prac-
ticing community well, offering clinicians a consensus
reference document that is potentially helpful in re-
solving predictably difﬁcult clinical dilemmas. It is our
expectation that the present conservative AHA/ACC
scientiﬁc statement will follow in that tradition. The ﬁnal
document was approved by all participants and assigned
outside reviewers.
IMPETUS FOR THE PRESENT DOCUMENT
There are a number of factors that support the decision to
update the 36th Bethesda Conference here (3). First,
sudden cardiac deaths in young healthy athletes remain
tragic and counterintuitive events, subject to persistently
high public visibility, emotion, and media scrutiny, with
potential legal liability considerations. Therefore, a strong
impetus remains to identify high-risk athletes to reduce
their exposure to sudden death risk. Indeed, there is
an ever-expanding population of competitive athletes,
including those participating in new and emerging orga-
nized sports. Second, cardiovascular medicine changes
rapidly. As evidence of this, in the almost 10 years sincepublication of the 36th Bethesda Conference (3), new
conditions associated with sudden death in the young
have been recognized, and knowledge of the responsible
diseases and inherent risks of sudden cardiac death in the
young has evolved (4–8). As a result, some selected areas
of the 36th Bethesda Conference may have become
obsolete, and novel issues not previously addressed, have
emerged. Third, an increasing number of adults with
congenital heart disease and cardiomyopathies are now
being recognized (often with surgical palliation or
correction) who wish to engage in competitive athletics
and require contemporary recommendations. In addition,
the increasing penetration into cardiovascular practice of
implantable devices (e.g., pacemakers and cardioverter-
deﬁbrillators) has created greater numbers of physically
active young people with genetic heart diseases who have
had devices implanted and who may aspire to participa-
tion in competitive athletics. Recently, there has been
greater deployment of automatic external deﬁbrillators at
athletic events in recognition of sudden death risk in
young athletes. Finally, the practicing cardiovascular
community deserves and expects the most up-to-date
information on which to make important clinical de-
cisions regarding eligibility versus disqualiﬁcation of
competitive athletes.
DEFINITIONS
As in the 3 Bethesda Conferences (1–3), the basic deﬁni-
tion of a competitive athlete remains unchanged: One
who participates in an organized team or individual sport
that requires regular competition against others as a
central component, places a high premium on excellence
and achievement, and requires some form of systematic
(and usually intense) training. Therefore, organized
competitive sports are regarded as a distinctive activity
and lifestyle. An important principle concerns whether
competitive athletes with either known or unsuspected
cardiovascular disease can be expected to properly judge
when it is prudent to terminate physical exertion. Indeed,
the unique pressures of organized sports do not allow
athletes to exert strict individual control over their level
of exertion or reliably discern when cardiac-related
symptoms or warning signs occur that should dictate
termination of the activity.
Furthermore, it is emphasized that these AHA/ACC
recommendations should not be regarded as a general
overriding injunction against all forms of exercise.
Notably, this document is concerned only with organized
and sanctioned competitive sports participation, such as
most commonly found in middle school, high school, and
college (1–3), and not with purely recreational physical
activities (9). The panel recognizes and strongly supports
the well-documented health beneﬁts of exercise, with
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who have been removed from organized competitive
athletics, or who elect to participate in a wide range of
recreational sporting activities.
Although the Bethesda Conferences and the present
document are largely focused on student-athletes of high
school and college age (primarily 12 to 25 years old), the
panel recognizes the need to also be more expansive with
regard to age of the athletes, that is, that participation in
competitive athletics now increasingly begins earlier in a
variety of youth sports before high school and continues
beyond college. This consideration is also substantiated
by the realization that inherited arrhythmia syndromes
can impact very young people and that patients with
genetic, congenital, or acquired heart diseases now
engage in competitive athletics at more advanced ages.
However, because systematic preparticipation screening
in the United States does not usually begin before high
school (4), recognition of cardiovascular disease in such
younger athletes is unpredictable.
CAUSES OF SUDDEN DEATH IN ATHLETES
The cardiovascular causes of sudden death in young
athletes have been well documented in forensic data-
bases (5–9). These deaths occur in both sexes (although
more commonly in males, by 9:1); in minorities, promi-
nently including African-Americans and in a wide range
of individual and team sports. In the United States,
among people <35 years old, genetic heart diseases
predominate, with hypertrophic cardiomyopathy being
the most common, accounting for at least one-third of
the mortality in autopsy-based athlete study populations
(5–7). Congenital coronary anomalies (usually those of
wrong sinus origin) are second in frequency, occurring in
z15% to 20% of cases. Other less common diseases, each
responsible for z5% or fewer of these sudden deaths,
include myocarditis, aortic valve stenosis, aortic dissec-
tion/rupture (including cases of the Marfan phenotype),
atherosclerotic coronary artery disease, ion channelo-
pathies, and arrhythmogenic right ventricular cardio-
myopathy. In addition, commotio cordis (i.e., sudden
death caused by blunt, nonpenetrating chest blows,
associated with structurally normal hearts) is more
common as a cause of sudden death in young athletes
than many of the aforementioned structural cardiovas-
cular diseases (10).
Regional variations in the causes of sudden death
may exist (6–9). Notable among these, arrhythmogenic
right ventricular cardiomyopathy has been reported as
the most common cause of sudden death in young
athletes based on reports from the Veneto region of Italy
(8), whereas this disease is a much less frequent cause
of sudden death in U.S. athletes (6). In most athletes,sudden death occurs in the setting of ventricular ﬁbril-
lation, with the notable exception of aortic dilation that
leads to dissection and rupture. For older athletes (>35
years of age), atherosclerotic coronary artery disease is
the predominant cause of sudden death (7), but this
occurs less frequently in younger participants.
HOW TO USE THE DOCUMENT
Of the 15 Task Forces that make up this document, 9 are
disease (or multidisease) related. As before (1–3), speciﬁc
recommendations for sports eligibility or temporary or
permanent disqualiﬁcation to reduce sudden death risk
are formulated around the classiﬁcation of sports (Task
Force 1), which incorporates the principle that training
and competition demands may vary considerably among
competitive sports (often within sports as well), that the
intensity of conditioning may exceed that of competition,
and that different levels of physical activity are likely
to impact underlying (and unsuspected) cardiovascular
diseases unpredictably and in different ways. Further-
more, it is difﬁcult to accurately grade or take into
account exercise intensity in various sports because of a
variety of factors, particularly motivational attitudes.
Finally, as was the practice in prior Bethesda Conferences
16, 26, and 36 (1–3), the panel advises that sports partici-
pation recommendations or decisions be based on prob-
able or conﬁrmed diagnostic evidence for cardiovascular
disease and not include diagnoses that are ambiguous,
possible, or borderline.
The other 6 Task Forces deal with a variety of relevant
topics and issues surrounding the risks of the athletic
ﬁeld. These include strategies for preparticipation
screening (Task Force 2), use of the automatic external
deﬁbrillator on the athletic ﬁeld (Task Force 12), the
impact of dietary supplements and performance-
enhancing substances (Task Force 11), commotio cordis
as an acknowledged new risk of sudden death during
sports (Task Force 13), and medical-legal perspectives
(Task Force 15). However, we should underscore that it is
not possible to foresee and include in this document
every conceivable cardiovascular abnormality or clinical
situation relevant to athletes. Eligibility and disqualiﬁ-
cation decisions in those particular situations would
be made on a case-by-case basis with individual clinical
judgment. Each of the 15 Task Forces is cited indepen-
dently as a publication in PubMed.
WHO SHOULD USE THIS DOCUMENT?
These recommendations are designed primarily for
cardiologists, internists, pediatricians, family medicine
physicians, and other practitioners (including team phy-
sicians) charged with decision-making responsibilities
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competitive athletes with cardiovascular disease.
Although this document essentially focuses on
disqualiﬁcation standards for trained competitive ath-
letes, particularly those in organized sanctioned pro-
grams, we also recognize that the principles espoused
herein may be, if appropriate, useful when translated to
physically active people in other circumstances, for
example, in occupations such as police ofﬁcers, ﬁre-
ﬁghters, and pilots (11), as well as to participants in
certain recreational sports activities. In this regard, it
should be underscored that many people independently
choose to engage in recreational physical activities that
may in fact involve high-intensity vigorous training at
the same level of some competitive athletes. Therefore,
the use of this document for decision making will
require certain judgments and extrapolations to account
for perceived differences in activity between trained
competitive athletes in organized sports and some other
physically active people. Hence, it may be possible to
selectively apply the principles contained in this docu-
ment to certain sporting activities that do not meet our
precise deﬁnition of “competitive.” Nevertheless, exces-
sive and unnecessary exercise restrictions for such people
with heart disease could potentially create physical and
psychological burdens (particularly in young children)
and are discouraged (9).
If the underlying medical considerations are similar to
high school- and college-aged athletes, the recommen-
dations in this document could be used to guide decisions
relevant to professional athletes with cardiovascular
abnormalities. However, professional athletes represent a
very small and unique subset of all competitive athletes
compared with the millions of student-athlete partici-
pants and are generally highly compensated adults with
employment contracts (12).
ASSESSMENT OF RISKS
Young people participating in competitive sports with
cardiovascular abnormalities have limited control when
exposed to extreme and unpredictable environmental
conditions (associated with alterations in blood volume,
hydration, and electrolytes), as a result of the unwavering
demands of sport. These circumstances can enhance the
risk for potentially lethal arrhythmias and sudden death,
given underlying cardiovascular disease. For many ath-
letes, removal from the lifestyle of athletic training and
competition will reduce this risk for sudden death or dis-
ease progression, even in the absence of established risk
factors related to their disease (13). However, appropriate
sports disqualiﬁcation is only one component of risk
reduction, and each of the relevant cardiovascular dis-
eases is attached to its own treatment algorithms, whichcan include prophylactic implantation of a cardioverter-
deﬁbrillator should sudden death risk be judged unac-
ceptably high (14–16).
The present recommendations, formulated with
respect to allowable levels of sports activity, can be
regarded as generally conservative. Certainly, this is a
prudent posture when the available evidence is limited in
many decision-making areas. In this regard, the panel
acknowledges that the available data support the princi-
ple that participation in high-intensity sports is associ-
ated with an increased relative risk of sudden death in the
setting of some cardiovascular diseases (6–17). On the
other hand, this likelihood cannot be determined with
certainty for each patient/athlete, and in fact may be low
in certain people. However, at present, additional risk-
stratifying tools are not available to independently (and
more precisely) guide many of these difﬁcult medical
decisions in athletes, particularly for diseases such as
hypertrophic cardiomyopathy (18).
Thus, it is possible that the recommendations of this
consensus panel (as with the 3 previous Bethesda Con-
ferences) (1–3) will occasionally cause some athletes to
be unnecessarily withdrawn from competition. This is,
of course, unfortunate, because athletes derive consid-
erable self-assurance, conﬁdence, physical well-being,
and even on occasion ﬁnancial security from these
activities. Nevertheless, the increased sudden death risk
associated with intense sports is a controllable variable
(by disqualiﬁcation from such sports), and we believe
the devastating impact on families and communities of
even infrequent sudden death events in this young
population underscores the wisdom of our conservative
recommendations.
In practice, individual athletes may be encouraged
to change their competitive sport involvement from a
prohibited high-intensity activity to a more permissible
low-intensity one (i.e., usually to class IA). However, the
strategy of changing the position in which an athlete
competes (e.g., from running back to place kicker in
football, or to goalie in hockey or soccer) may be difﬁcult
to accomplish in practical terms and therefore should be
advised only if the training obligations outside of game
situations can be controlled and modiﬁed adequately.
RELATION OF AHA/ACC GUIDELINES
TO 36TH BETHESDA CONFERENCE
The present AHA/ACC recommendations are intended
to update (and are derived from) the prior Bethesda
Conferences (1–3). For the most part, the speciﬁc recom-
mendations are similar or identical to those in the report
on the 36th Bethesda Conference (3). However, selected
recommendations of the present AHA/ACC document
do in fact deviate from those of the 36th Bethesda
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2347Conference, becoming less restrictive as certain data
and observations have emerged since 2005. Nevertheless,
numerous “gray areas” persist, for which the assessment
of safe versus nonsafe sports participation continues to
be uncertain from a medical and scientiﬁc perspective,
with absolute certainty difﬁcult to achieve for many
cardiovascular issues. This may result in differences of
opinion among physicians regarding the exercise of
clinical judgment in individual cases. Thus, in making
certain eligibility or disqualiﬁcation decisions, some
physicians may rely on the more liberal guidelines in
portions of the present document, whereas others may
take a more conservative approach by adopting the more
restrictive recommendations from the 36th Bethesda
Conference.
It is also important to underscore that the recommen-
dations in this AHA/ACC document are not intended to
establish absolute mandates or the general medical (and
legal) standard of care applicable to all cases. These rec-
ommendations do not (and cannot) absolutely and arbi-
trarily replace individual clinical judgment and informed
medical reasoning.
The panel recognizes that some practitioners,
depending on their perception of risk for speciﬁc indi-
vidual patients, may choose to prudently deviate from the
published recommendations in selected clinical situa-
tions. Therefore, fully informed athletes with certain
conditions may continue to engage in competitive sports
in concert with recommendations made by their physician
and athletic organization (i.e., high school or college).
Individual athletes in the past have taken this option to
continue or return to play, and we anticipate this will
occur in the future. There will always be tolerance in the
system for some ﬂexibility and individual responsibility
and choice, after the prevalent uncertainties have been
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